News >

Pertuzumab and Other Agents Continue Progress in HER2+ Breast Cancer

Danielle Bucco
Published: Tuesday, Jan 02, 2018

Adam M. Brufsky, MD, PhD

Adam M. Brufsky, MD, PhD
The adjuvant treatment landscape for patients with HER2-positive breast cancer continues to grow, particularly following the recent FDA approval of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and chemotherapy, which was based on findings from the APHINITY trial.

, Adam M. Brufsky, MD, PhD, a professor of medicine, associate chief of hematology/oncology, co-director of the Comprehensive Breast Care Center, associate director of clinical investigation, University of Pittsburgh, discussed the developing role of pertuzumab in HER2-positive breast cancer, as well as the impact of other agents in the field.

OncLive: Can you discuss the impact of pertuzumab on the treatment landscape for patients with HER2-positive breast cancer?

Brufsky: Many oncologists in the United States will treat patients with neoadjuvant chemotherapy. The reason we have done that is because it was the only setting in which pertuzumab was approved until recently. If we decide someone needs anti-HER2 therapy and chemotherapy, we generally will give them either docetaxel, carboplatin, trastuzumab (Herceptin), and pertuzumab (TCHP) or Adriamycin and cyclophosphamide (AC) times 4 followed by THP. That would be 4 to 6 cycles of a pertuzumab-containing regimen. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication